TrialThe Lancet. Respiratory medicine2022
Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.
Aurélien Mazeraud et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
39 papers cite it
this paperpooled ittrialcites it